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Abstract
Background: Antibiotic resistance genes can be targeted by antisense agents, which can reduce their expression
and thus restore cellular susceptibility to existing antibiotics. Antisense inhibitors can be gene and pathogen specific,
or designed to inhibit a group of bacteria having conserved sequences within resistance genes. Here, we aimed to
develop antisense peptide nucleic acids (PNAs) that could be used to effectively restore susceptibility to β-lactams in
methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus pseudintermedius (MRSP).
Results: Antisense PNAs specific for conserved regions of the mobilisable gene mecA, and the growth essential gene,
ftsZ, were designed. Clinical MRSA and MRSP strains of high oxacillin resistance were treated with PNAs and assayed for
reduction in colony forming units on oxacillin plates, reduction in target gene mRNA levels, and cell size. Anti-mecA
PNA at 7.5 and 2.5 μM reduced mecA mRNA in MRSA and MRSP (p < 0.05). At these PNA concentrations, 66 % of MRSA
and 92 % of MRSP cells were killed by oxacillin (p < 0.01). Anti-ftsZ PNA at 7.5 and 2.5 μM reduced ftsZ mRNA in MRSA
and MRSP, respectively (p≤ 0.05). At these PNA concentrations, 86 % of MRSA cells and 95 % of MRSP cells were killed
by oxacillin (p < 0.05). Anti-ftsZ PNAs resulted in swelling of bacterial cells. Scrambled PNA controls did not affect MRSA
but sensitized MRSP moderately to oxacillin without affecting mRNA levels.
Conclusions: The antisense PNAs effects observed provide in vitro proof of concept that this approach can be used to
reverse β-lactam resistance in staphylococci. Further studies are warranted as clinical treatment alternatives are needed.
Keywords: Antisense, mecA, ftsZ, MRSA, Methicillin-resistant Staphylococcus pseudintermedius
Background
Antimicrobial resistant bacteria threaten the health of
humans and animals by limiting treatment options dur-
ing infection [1]. Resistance can arise through spontan-
eous mutation or through the acquisition of resistance
genes by horizontal transfer [2]. Given limited success in
the development of new antimicrobial drugs, there is
great interest in targeting resistance genes to re-establish
susceptibility to existing antibiotics [3, 4]. This strategy
is attractive because it would reduce the need to de-
velop new classes of antimicrobials, but it requires
the development of clinically effective and safe inhibi-
tors of resistance. Several laboratories have pursued
the idea of reducing expression of resistance genes so
that the amount of protein conferring resistance is re-
duced to a level that re-sensitizes the bacterium [5].
If successful, this approach could provide a generic
strategy applicable to a wide range of resistance genes
that cause clinical problems.
Staphylococcal infections are amongst the most com-
mon presentations in human and veterinary medicine
that lead to prescription of antimicrobial drugs [6–8].
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The predominant staphylococcal species involved with
disease would typically be susceptible to most classes
of antimicrobial agents, e.g. S. aureus in humans and
S. pseudintermedius in pets. However their methicillin-
resistant counterparts, MRSA and MRSP, tend to be re-
sistant to most clinically relevant antimicrobial drugs and
both species have zoonotic potential [9, 10]. In MRSA and
MRSP, resistance to methicillin and other β-lactams is
conferred by mutated versions of the penicillin-binding
protein (PBP2a). PBP2a is located within the bacterial cell
wall and has low affinity to all β-lactam-antimicrobials
[11], rendering them ineffective [12]. PBP2a is encoded by
mecA, which is conserved amongst different staphylococ-
cal species and located on a staphylococcal cassette
chromosome (SCC). Hence it may be possible to develop
a common strategy for inhibiting mecA expression in
these pathogens and re-sensitize staphylococci.
PNAs are a type of synthetic DNA mimic that bind
strongly to single-stranded nucleic acids, and are highly
resistant to nucleases and proteases. They have been
studied as antimicrobials through silencing of bacterial
growth essential genes [5, 13, 14]; however growth in-
hibitory doses in MRSA were relatively high [14], risking
non-specific effects. PNA has not been tested for revers-
ing antibiotic resistance in staphylococci, but reversion
by antisense phosphorothioate oligodeoxynucleotides (PS-
ODN) and protein inhibitors has been reported [15, 16].
The use of antisense agents on MRSP has not been re-
ported. The next step is to develop more potent inhibitors
that can be considered for clinical development; e.g. top-
ical medications to reverse resistance to beta-lactam drugs
that are given systemically or locally. Although PNA syn-
thesis is currently expensive, the relative risk and cost of
finding and developing new classes of antibiotics could be
higher [17]. If used clinically, the cost of large scale PNA
synthesis is likely to reduce with advancing technology
and methods. This was the case for penicillin, where the
cost of a dose reduced from US$20 in 1943 (equivalent to
US$287 in 2014) to US$0.25 in 2014 [18].
In this study we tested whether or not antisense PNA
against two gene targets, mecA and ftsZ, could sensitize
MRSA and MRSP to oxacillin. The anti-mecA PNA
resulted in sensitization to oxacillin and mecA mRNA
reduction in both MRSA and MRSP. The anti-ftsZ
PNA resulted in cell swelling, growth inhibition, ftsZ
mRNA reduction, and sensitization to oxacillin at lower
concentrations than previously reported.
Methods
Bacterial growth
The MRSA strain NCTC 13142 from Public Health
England Culture Collections is a UK epidemic strain
type EMRSA-15, SCCmec Type IV, and the MRSP
strain HH-1 was isolated from a canine skin infection
and is ST71, SCCmecII-III [19]. Bacteria were cul-
tured on Columbia base agar (Oxoid, Basingstoke,
UK) supplemented with 5 % horse blood (Oxoid) and
6 μg/ml oxacillin (Sigma Aldrich, UK) at 35 °C for
20 h. Overnight broth cultures were prepared from
single bacterial colonies inoculated in 3 ml Mueller
Hinton broth (MHB, Oxoid) supplemented with
6 μg/ml oxacillin and incubated at 35 °C for 20 h at
180 rpm on a rotary shaker.
Antibiotic susceptibility assays
The MIC of oxacillin was determined by broth microdilu-
tion according to CLSI guidelines [20]. Briefly, overnight
broth cultures of MRSA and MRSP were standardized to
OD625 = 0.08–0.09 (equivalent to 10
8 CFU/ml) in MHB
and further diluted 100-fold to obtain 106 CFU/ml. The
bacterial suspension was then inoculated at 50 μl per well
to a final concentration of 5 × 105 CFU/ml. Two-fold serial
dilutions of oxacillin (2–512 μg/ml) were added to bacter-
ial cultures at 50 μl per well to a final volume of 100 μl
per well, and 96 well plates were incubated at 35 °C for
24 h. MICs were visually scored.
Antisense PNA design
To design antisense PNAs complementary to mecA or ftsZ
mRNAs in both MRSA and MRSP, the −20 to +20 region
of the start codon that included the Shine Dalgarno (SD)
and 5′ end sequences of mecA or ftsZ from several isolates
of MRSA and MRSP were aligned using ClustalW2. Con-
sensus sequences of conserved regions were analysed for
specificity in the MRSA N315 genome in the GenoList
database [21]. Although this database has limited ge-
nomes, we used it for sequence alignments to relevant SD
regions of a genome in an antisense orientation, with spe-
cified numbers of mismatch bases.
Genomic DNA extraction and PCR
Genomic DNA (gDNA) was extracted from 1 ml of over-
night cultures using the Gentra Puregene Yeast/Bacteria
kit (Qiagen). PCR was carried out on gDNA to determine
the sequence of the mecA PNA target region (i.e. SD re-
gion and 5′ end of mecA) with primers mecA-99F and
mecA-528R for both NCTC 13142 and HH-1 (Additional
file 1: Table S1). To determine the sequence of the ftsZ
PNA target regions (i.e. SD region and 5′ end of ftsZ),
primers E15ftsZ_F and E15ftsZ_R specific for NCTC
13142, and ED99ftsZ_F and EDftsZ_R specific for HH-1
were used (Additional file 1: Table S1). PCR was carried
out with Crimson Taq DNA polymerase (New England
Biolabs) with cycling conditions of 95 °C for 5 min, 35 cy-
cles of 95 °C for 30 s, 52 °C (mecA primers) or 61 °C (ftsZ
primers) for 30 s, 68 °C for 1 min, and a final extension of
68 °C for 5 min.
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Oxacillin sensitization assays
Overnight broth cultures were adjusted to 5 × 105 CFU/
ml per well of a 96 well plate as described above and
used either in a broth growth assay or a viable count
assay. The broth growth assay was used as an initial
screen of PNA efficacy because it was simple to carry
out. In the broth assay, 1 8= , ¼, ½, 1 ×MIC of oxacillin
was used in the bacterial cultures (i.e. 64, 128, 256,
512 μg/ml oxacillin for NCTC 13142 or 128, 256, 512,
1024 μg/ml oxacillin for HH-1). Anti-mecA PNAs were
added at either 2.5 or 5 μM. After incubation at 35 °C
for 24 h, the MIC of oxacillin in combination with the
PNAs in broth cultures were scored visually as recom-
mended by CLSI guidelines [20].
The viable count assay is more sensitive than the broth
assay and was used to assess the effects of PNAs that
performed well in the initial screen described above. In
the viable count assay, 5 × 105 CFU/ml per well of cul-
ture was treated either with 2.5, 5 and 7.5 μM of PNA
for NCTC 13142, or 1, 2.5 and 5 μM of PNA for HH-1
in MHB at 35 °C for 6 h. Cultures were serially diluted
in PBS and 100 μl of 10−3, 10−4, 10−5, 10−6 dilutions
were spread-plated onto MH agar supplemented with
16 μg/ml oxacillin, which was determined to be the
highest selective but not growth inhibitory concentration
for this assay. Agar plates were incubated at 35 °C for
24 h, and dilutions resulting in 30–300 colonies per
plate were used to determine the viable count. Experi-
mental repeats were carried out on separate days, and
reductions in CFU of treated cultures were normalized
to CFU of the untreated control culture on the day. Stat-
istical analysis of CFU reductions was carried out with
the paired Student’s t-Test in Microsoft Excel.
Growth inhibition assays
Anti-ftsZ PNAs were tested for effects on growth. Over-
night MHB cultures were adjusted to 5 × 105 CFU/ml
per well of a 96 well plate in MHB supplemented with
6 μg/ml oxacillin as described above. Anti-ftsZ PNA was
added to final concentrations of 0, 1, 2.5, 5, 7.5 μM and
incubated in a microplate reader (Spectramax 340PC,
Molecular Devices) at 35 °C for 6 h. The optical density
of the cultures was monitored at 550 nm with readings
every 5 min after shaking for 5 s.
Light microscopy
Bacterial cultures were treated with anti-ftsZ PNA Z46 in
broth as described in the viable count assay. After 6 h at
35 °C, cultures were pelleted, washed once in PBS, and re-
suspended in 1/10 of original volume of the culture in
PBS. Ten microliter aliquots were heat-fixed, Gram
stained, and viewed under a light microscope (Olympus
BX60) at 1000 ×magnification. Images were captured
using the Image-Pro Plus 5.0 (MediaCybernetics), and
counting of purple and pink cells were carried out using
ImageJ 1.44o (National Institute of Health, USA).
RNA extraction, cDNA synthesis and qPCR
Growth of cultures in a 96 well plate was monitored by
reading the optical density at 550 nm every 5 min, after
shaking for 5 s in a microplate reader (Spectramax
340PC, Molecular Diagnostics). Cultures were harvested
when the untreated control culture increased in OD550 ≈
0.1. Cultures with the same PNA treatment but in differ-
ent wells across the 96 well plate were pooled for total
RNA extraction and DNase I treatment (Ribopure™
Bacteria kit, Life Technologies). RNA was checked for
gDNA contamination by qPCR using gyrA primers
(Additional file 1: Table S1) and SsoFast™ EvaGreen®
Supermix (Bio-Rad) before cDNA synthesis using 50 ng
RNA and iScript™ Reverse Transcription Supermix (Bio-
Rad). Samples of cDNA were diluted 10-fold and 4 μl
used in each qPCR reaction. Non-template controls were
included for each primer pair in each run, and technical
duplicates for each sample were included in each run.
Validation of primers for qPCR
Primer pairs for qPCR were designed by Primer3 with
a Tm of 60 °C and product sizes of 100–200 bp
(Additional file 1: Table S1). Gene sequences were
taken from genome assemblies of S. aureus HO 5096
0412 (GenBank NC_017763.1), an EMRSA-15 strain, and
S. pseudintermedius ED99 (GenBank NC_017568.1), a
methicillin sensitive S. pseudintermedius strain, as anno-
tated genome sequences of MRSP strains were not pub-
licly accessible at the time of assay design. Similarities of
these gene sequences were later confirmed to match
MRSP E140 (Genbank accession NZ_ANOI01000001) se-
quences. Primer concentrations (300–500 nM) were opti-
mized for use in SsoFast™ EvaGreen® Supermix in a
CFX96 Real-time PCR Detection System with CFX Man-
ager v2 (Bio-Rad), with 5 ng cDNA per reaction. Primer
efficiencies were determined using 10-fold serial dilutions
of cDNA (10 pg-1 μg). Melt-curve analyses were carried
out for all reactions.
Validation of reference genes and analysis of mRNA levels
by RT-qPCR
Total RNA and cDNA were prepared as described above.
Raw Cq values were analysed in qbase + (Biogazelle,
Belgium) with user-defined primer efficiencies (Additional
file 1: Table S1) and expression stabilities (M value) of
each candidate reference gene fabD, gyrA, proC, pta, pyk,
rho, sodA, and tpiA were calculated as the average pair-
wise variation for each gene with all other tested genes
[22]. Low M values indicate stable expression. Stepwise
exclusion of the gene with the highest M value allowed
ranking of the tested genes according to their expression
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stability, and from this the optimal number of reference
genes was calculated [22]. To measure the expression
levels of genes conditionally silenced by antisense PNA,
Cq values were normalized against the two most stably
expressed references genes with user-defined PCR effi-
ciencies (Additional file 1: Table S1) in qbase + (Bioga-
zelle). Relative mRNA levels were then calculated as
induced normalized Cq/uninduced normalized Cq, and
analysed with paired Student’s t-Test in Microsoft Excel.
Results
Anti-mecA PNA sensitization of MRSA and MRSP to
oxacillin
Alignment of the mecA start codon region of selected S.
aureus and S. pseudintermedius strains showed 100 %
alignment in all except the USA300 and livestock-
associated MRSA ST398 (Additional file 2: Figure S1).
As we were interested in the major UK epidemic strain
NCTC 13142 (EMRSA-15, ST22, SCCmecIV) [23, 24],
and the first genetically well-characterized clinical MRSP
strain, HH-1 (ST71, SCCmecII-III) [19], we based our
antisense designs on sequence alignments on these
strains. Sequences of the PNA target regions in NCTC
13142 and HH-1 were additionally determined by PCR
and sequencing to confirm that the antisense design was
appropriate. Four anti-mecA and one scrambled PNA
were designed and conjugated to the cell-penetrating
peptide (CPP) KFFKFFKFFK (Table 1). Initial screening
at low and sub-optimal concentrations of the four anti-
mecA PNAs showed that A73 was the most effective and
sensitized NCTC 13142 and HH-1 broth cultures to
oxacillin by 4–8 fold at 2.5–5 μM (Additional file 1:
Table S2). More sensitive viable count assays were then
carried out to further examine the activity of A73.
The most effective antisense PNA (A73) and a
scrambled sequence (scrA) were conjugated to two
other CPPs to test for their ability to improve deliv-
ery: EJH-L1 (MINWKLRLKNK) and HIV 1-Tat
(YGRKKRRQRRR) (Table 1). The (RXR)4XB peptide
was not included because it could inhibit growth in-
dependently of the antisense PNA [14]. The EJH-L1
peptide was derived from a Streptococcus pneumo-
niae phage holin protein, shown to make lesions on
lipid vesicles and cause cell death in S. pneumoniae
and E. coli [25]. The HIV-1 Tat peptide improved
antisense PNA effects compared to (KFF)3K in
Streptococcus pyogenes [26] (Table 1). However, we
observed that A73-EJH and A73-Tat PNAs sensitized
NCTC 13142 or HH-1 to oxacillin only by 2-fold, while
scrA-EJH and scrA-Tat did not have an effect in broth
microdilution assays (data not shown). Since this was not
an improvement over the sensitization observed using the
(KFF)3K peptide as carrier, subsequent experiments were
carried out using A73.
An assay based on CFU of bacteria was used to quantify
cell viability on oxacillin. The viability assay showed that
treatment with A73 led to sensitization of NCTC 13142
and HH-1 to oxacillin (Fig. 1). NCTC 13142 cells were
significantly sensitized to oxacillin at 2.5 μM (p = 0.015),
5 μM (p = 0.003) and 7.5 μM (p = 0.007) of A73 compared
to the same concentrations of scrA (p = 0.062, p = 0.037,
p = 0.122 respectively, Fig. 1). HH-1 cells were signifi-
cantly sensitized to oxacillin at 1, 2.5 and 5 μM of
A73 (p = 0.013, p = 1.15 × 10−4, p = 2.1 × 10−5 respectively,
Fig. 1). ScrA also resulted in significant sensitization at the
same concentrations (p = 0.04, p = 0.019, p = 0.002 re-
spectively, Fig. 1).
Anti-mecA PNA reduction of mecA mRNA
To determine whether A73 specifically reduced mecA
transcript levels, qPCR was carried out on PNA
treated and untreated cultures. First it was important
to determine the most appropriate MRSA and MRSP
reference genes under these experimental conditions
for normalization and relative quantitation of mecA
mRNA levels. We tested the expression levels of seven
candidate reference genes chosen from the literature
[27, 28] on the following samples: NCTC 13142 un-
treated and treated with 5 and 7.5 μM of A73, scrA,
Z46, scrZ, and HH-1 untreated and treated with 1 and
2.5 μM of A73, scrA, Z46 and scrZ. The two most sta-
bly expressed genes (i.e. having the lowest geNorm M-
values, [29]) were pta and gyrA for NCTC 13142, and
proC and pyk for HH-1 (Additional file 1: Table S3)
[29]. These genes were used to normalize quantitative
real-time PCR (qRT-PCR) data in NCTC 13142 and
HH-1 samples, and showed that mecA mRNA was spe-
cifically reduced by A73 and not by scrambled PNA in
Table 1 Antisense PNAs used in this study
PNA 5′ − > 3′ sequence Target gene
(target region
around ATG)
A55 KFFKFFKFFK-eg1-ttcatcaata-CONH2 mecA (−5 to +5)
A73 KFFKFFKFFK-O-catcaatatc-CONH2 mecA (−7 to +3)
A82 KFFKFFKFFK-eg1-atcaatatcc-CONH2 mecA (−8 to +2)
A101 KFFKFFKFFK-O-caatatcctc-CONH2 mecA (−10 to −1)
scrA KFFKFFKFFK-O-cactataatc-CONH2 N.A.
A73-EJH MINWKLRLKNK-O-catcaatatc-CONH2 mecA (−7 to +3)
scrA-EJH MINWKLRLKNK-O-cactataatc-CONH2 N.A.
A73-Tat YGRKKRRQRRR-O-catcaatatc-CONH2 mecA (−7 to +3)
scrA-Tat YGRKKRRQRRR-O-cactataatc-CONH2 N.A.
Z19 KFFKFFKFFK-eg1-TTCTAACATT-NH2 ftsZ (−1 to +9)
Z46 KFFKFFKFFK-eg1-TAACATTTAA-NH2 ftsZ (−4 to +6)
scrZ KFFKFFKFFK-eg1-AATTACTATA-NH2 N.A.
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both bacterial species (Fig. 2). Similar to the sensitization
assay, a higher PNA dose was required for NCTC 13142
compared to HH-1: A73 at 5 μM reduced mecA tran-
scripts in NCTC 13142 by an average of 38 % (p = 0.02),
while 2.5 μM reduced mecA transcripts in HH-1 by an
average of 40 % (p = 0.002). However, in contrast to the
sensitization assay, the scrambled PNA did not have a sig-
nificant effect in HH-1 (p = 0.42 for 2.5 μM, Fig. 2). For
mRNA analysis, cultures were treated with A73 in the ab-
sence of oxacillin because the expression of mecA has
been shown to increase in the presence of its protein in-
hibitors, such as oxacillin, particularly for isolates with
functional regulatory genes, including HH-1 (ST71,
SCCmecII-III) [30, 31]. To accurately quantify mecA silen-
cing by PNAs, it was important to avoid possible
oxacillin-mediated upregulation of mecA.
Growth inhibition and sensitization of MRSA and MRSP to
oxacillin by anti-ftsZ PNA
Inhibitors of the cell division protein FtsZ have been
shown to sensitize MRSA to oxacillin [16]. In addition,
FtsZ is of interest as an antimicrobial target as it is a cell
division protein [32]. The ftsZ gene is essential for cell
division and growth in S. aureus, and hypothesized to be
essential in S. pseudintermedius based on bioinformatics
analysis. Although the nucleotide sequence of ftsZ in S.
pseudintermedius is different to that in S. aureus, the
ftsZ SD region (i.e. −20 to +20 about start codon) was
95 % conserved across selected MRSA and S. pseudinter-
medius strains (Additional file 2: Figure S2). This pro-
vides an opportunity to design PNAs that can target ftsZ
in both bacterial species. Inhibition of FtsZ protein leads
to a defect in cell division, resulting in growth inhibition
and swollen cell morphology [33], and we predicted that
silencing of ftsZ mRNA would have similar effects.
Prior to testing anti-ftsZ PNAs for sensitization to oxa-
cillin, we monitored effects on growth. Two anti-ftsZ and
one scrambled (scrZ) PNA conjugated to the (KFF)3K
peptide were tested on NCTC 13142 and HH-1 (Table 1).
Z19 was ineffective against NCTC 13142 but Z46 inhib-
ited NCTC 13142 growth at 7.5 μM and HH-1 growth at
2.5 μM (Fig. 3a & c). The scrambled PNA, scrZ, reduced
the growth rate of NCTC 13142 at 7.5 μM but was not
growth inhibitory (Fig. 3b). However, scrZ was growth in-
hibitory for HH-1 at 2.5 μM (Fig. 3d). Another phenotype
associated with FtsZ depletion is cell swelling [32], hence
Z46-treated cultures were Gram stained and examined
microscopically. NCTC 13142 and HH-1 cells not only
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Fig. 1 Sensitization of MRSA and MRSP to oxacillin by anti-mecA PNA. a Oxacillin resistant NCTC 13142 reduced in CFU with increasing concentrations
of anti-mecA PNA, A73, while the scrambled PNA, scrA, did not have an effect. b Oxacillin-resistant HH-1 reduced in CFU with increasing concentrations
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appeared swollen, but a greater proportion of cells also ap-
peared lysed or stained pink at 7.5 and 2.5 μM, respect-
ively, compared to untreated or scrZ-treated cells (Fig. 4a
& b). The heterogeneous shape and staining of cells prob-
ably indicate different stages of cell death and cell wall dis-
integration. It has been shown that FtsZ recruits PBP2a in
cell wall synthesis, and the depletion of FtsZ results in a
loss of cell wall integrity [32].
Target gene product specificity of Z46 was shown
through transcript analyses of Z46-treated cultures,
which had reduced ftsZ mRNA levels in NCTC 13142 at
7.5 μM and HH-1 at 2.5 μM, compared to untreated or
scrZ-treated cells (Fig. 5). Finally, we tested whether si-
lencing of ftsZ had the same effect on cell sensitization
to oxacillin as that reported for a FtsZ inhibitor [16].
Consistent with reversion of a resistance, we saw a re-
duction in CFU for all doses of silencer used, compared
to an untreated control. Treatment with Z46 at 7.5 μM
(p = 0.001) significantly sensitized NCTC 13142 to oxa-
cillin compared to scrZ at 7.5 μM (p = 0.012, Fig. 6a).
Treatment with Z46 at 0.5, 1 and 2.5 μM significantly sen-
sitized HH-1 to oxacillin (p = 0.02, p = 0.01, p = 0.026,
respectively) compared to scrZ at the same doses (p =
0.02, p = 0.98, p = 0.89, respectively, Fig. 6b).
Discussion
We aimed to develop antisense PNAs that could provide
potent and gene specific silencing of target genes within
both MRSA and MRSP. As the CPP component of
peptide-PNAs has been shown to improve potency, we
tested two new peptide carriers in addition to the our
standard KFF3K peptide: the HIV 1-Tat peptide and the
EJH-L1 peptide, based on previously shown cell pene-
trating activities in related bacterial species. However,
neither peptide resulted in an improvement in the silen-
cing of mecA in NCTC 13142 and HH-1. It is known
that teichoic acids in the peptidoglycan can be altered in
D-alanine content to increase positive charge of cell
walls, resulting in charge repulsion of and increased re-
sistance against cationic antimicrobial peptides [34]. In-
deed some MRSA strains possess thickened cell walls
and increased D-alanine production [35]. It is possible
that the NCTC 13142 strain tested in this study had
similar cell wall alterations, reducing the activity of
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Fig. 3 Phenotypic growth effect of anti-ftsZ PNA on MRSA and MRSP. Growth inhibition, an expected phenotypic effect of FtsZ depletion, was
observed in NCTC 13142 at 7.5 μM of anti-ftsZ PNA, Z46 (a) but less so at the same concentration of the scrambled PNA, scrZ (b). Growth of HH-1
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cationic CPPs conjugated to PNAs. A closer examination
of cell wall properties of NCTC 13142, along with test-
ing of CPPs of different structures may be required to
identify CPPs that display comparable activity in Gram
positive bacteria, as in Gram negative bacteria [36].
In the MRSP strain HH-1, PNAs were effective at
much lower concentrations compared to NCTC 13142.
This is presumably due to differences in cell wall struc-
tures, as passage across the cell wall is considered to be
the main limiting factor for PNA efficacy. Another indi-
cation of cell wall differences is that scrambled PNAs af-
fected cell viability of HH-1 without affecting transcript
levels of mecA or ftsZ (i.e. non-specific toxic effect). A
recent study showed the MIC of the (KFF)3K peptide
against MRSP isolates was 2–8 μM [37], which support
our observations of a non-specific toxic effect at 2.5 μM
of peptide-conjugated PNA. There is limited information
on the cell wall structure of MRSP, although genome
comparisons of S. pseudintermedius to S. aureus identi-
fied unique cell wall proteins in S. pseudintermedius re-
lated to canine cell adherence [38]. However, differences
in cell wall structure and components of S. pseudinter-
medius, MRSP and MRSA have not been examined.
Hence it is difficult to speculate whether D-alanylation
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Fig. 4 Phenotypic effect of anti-ftsZ PNA on cell morphology of MRSA and MRSP. a Swollen cells (purple arrow), an expected phenotypic effect
of FtsZ were observed in Z46-treated cultures, while untreated and scrZ-treated cultures appeared normal. A larger number of Z46-treated cells
stained pink (red arrow) compared to scrZ-treated cells; untreated cells did not stain pink. Scale bar = 1 μm. b Gram stained cells from three frames
were counted with Image J and mean ± SD values are shown
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is contributing to the observed sensitivity to PNAs, as
discussed for MRSA.
The A73 and Z46 PNAs specifically reduced target
mRNA when corresponding scrambled controls did not
(excluding general toxicity of 5 μM Z46 and scrZ on
HH-1). Although mRNA reduction was low, the pheno-
type observed was consistent with gene requirement for
resistance maintenance, indicating the important role(s)
of mecA and/or ftsZ in resistance to oxacillin. This ob-
servation is similar to the effect of silencing lacZ and
some essential genes in Escherichia coli, where a small
reduction in mRNA results in a proportionally larger
protein/phenotypic effect, due to translation repression
or a high requirement for gene expression to maintain
physiological functions [14, 39, 40]. In comparing the
sensitization effects on epidemic MRSA and MRSP
strains of high resistance (MIC ≥ 256 mg/L oxacillin)
through silencing of two known targets (mecA, ftsZ), we
found the mRNA levels of both gene targets in both spe-
cies were reduced to similar levels with PNA treatment.
Yet in NCTC 13142, silencing of ftsZ led to greater oxa-
cillin sensitization, while in HH-1 silencing of mecA
achieved greater sensitization. This may be due to the
different ways in which mecA expression is regulated in
NCTC 13142 and HH-1. NCTC 13142 harbours
SCCmec IV, which contains a truncated mecR1 and lacks
mecI and mecR2. Hence mecA is constitutively expressed
[31] and may be saturating anti-mecA PNA activity dur-
ing cell division. HH-1 harbours SCCmec II-III, which
contains intact regulatory genes mecR1, mecI and mecR2
so that mecA expression is induced upon exposure to
oxacillin [31]. As the sensitization assay involves expos-
ing HH-1 to anti-mecA PNA before plating bacterial cul-
tures onto oxacillin plates, it is less likely that the
activity of anti-mecA PNA was saturated before cells
divided. Alternatively, sensitization differences may be
due to different growth kinetics for NCTC 13142 and
HH-1. NCTC 13142 has a higher growth rate than HH-
1 (Fig. 3), hence ftsZ silencing of NCTC 13142 could
have a greater impact on cell division and cell wall syn-
thesis leading to a greater sensitization effect.
Two previous studies examined the use of antisense
PNAs in MRSA, targeting essential genes to achieve
growth inhibition at 12.5–40 μM [14, 41]. This is the
first study on the use of PNA for sensitizing MRSA and
MRSP to oxacillin. Re-sensitization of MRSA to β-lactams
was examined using an anti-mecA phosphorothioate
oligonucleotide (PS-ODN) [15]. The data indicate that
further improvements are needed, and studies on alterna-
tive technical approaches should increase the chances of
success in resistance reversal strategies. Advantages of
PNA over PS-ODN include higher binding affinity to
RNA, greater convenience in formulation/usage as it does
not require liposome encapsulation, and higher resistance
to nucleases [42]. On the other hand, PS-ODNs are
already used clinically for an anti-viral (Vitravene®), and an
anti-cholesterol therapy (Kynamro®).
When developing topical medications for clinical use,
bioavailability considerations are less relevant and PNAs
have suitable properties because they are stable in bio-
logical fluids [43], effective when administered locally in
murine models at concentrations similar to those used
in this study [44], soluble in water at those concentra-
tions, and have a long post-antibiotic effect [45]. The
effective concentration of PNAs used in this study is the
lowest reported for MRSA in vitro, at 7.5 μM, and the
first reported for MRSP in vitro, at 2.5 μM. With
molecular weights of 4211.5 and 4250.5 for A73 and
Z46, respectively, 2.5–7.5 μM concentrations may be
feasible for developing topical medication for clinical
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Fig. 6 Sensitization of MRSA and MRSP to oxacillin by anti-ftsZ PNA. a CFU of NCTC 13142 was reduced by 87 % at 7.5 μM of anti-ftsZ PNA, Z46
compared to a reduction of 44 % by the scrambled PNA, scrZ. b CFU of HH-1 reduced significantly at all concentrations of Z46 compared to scrZ,
except at 5 μM where Z46 and scrZ had similar effects. Relative CFU reduction was calculated as a ratio to an untreated control in each
experiment. Values shown are mean ± SD, n = 3. *p < 0.05, **p < 0.01
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use. Hence these PNAs can be taken forward in further
testing of toxicity and efficacy in vitro, ex vivo or in vivo
in suitable animal models.
Conclusions
Antisense PNAs targeting conserved regions in mecA
and ftsZ of Staphylocci strains NCTC 13142 and HH-1
were able to re-sensitize cells to oxacillin, and inhibit the
growth of cells at lower concentrations than previously
reported. This study also shows for the first time that
antisense PNAs are effective gene-silencers in a clinical
MRSP isolate. However, a scrambled PNA affected HH-
1 cell viability in a non-specific way, suggesting cell wall
sensitivity to the CPP. It may be possible to use PNAs to
develop pathogen selective antimicrobials for the topical
treatment of skin infections. However, testing of add-
itional antisense molecules against more clinical isolates
of MRSA and MRSP is needed to evaluate the practical-
ity of this approach.
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